REGLYDE: A Clinical Trial to Enhance the Brain's Natural Defenses in Alzheimer's
Together, let's advance innovative, non-invasive brain therapy
ALZHEIMER'S
The Challenge: A Devastating Disease
Alzheimer’s disease shatters lives, robbing millions of their memories, their independence, and the essence of who they are.
It’s a crisis that extends beyond individuals, placing an immense emotional and physical burden on their families and loved ones.
Imagine if there was a way to restore hope, offering a chance to reclaim memories, bring back our loved ones, and embrace life once again.
We have made a significant discovery that could forever change how we think about Alzheimer’s. It’s time to stop fighting the brain and start working with it!
ALZHEIMER'S
Our Hypothesis
The brain consumes large amounts of energy and generates waste products that must be efficiently cleared to maintain function and health. This process depends on cerebrospinal fluid (CSF), a clear fluid that surrounds the brain and spinal cord while delivering nutrients and removing toxins. Spinal movements play a crucial role in driving CSF circulation, a natural mechanism our bodies support through regular physical activity.
Unfortunately, modern sedentary lifestyles disrupt this essential circulation, contributing to reduced nutrient delivery, toxic buildup, and an increased risk of neurodegenerative diseases like Alzheimer’s. Traditional movement philosophies like yoga and qigong intuitively recognized the importance of spinal movements for mental and cognitive well-being.
At Ciatrix, we’re integrating these ancient practices with the latest advancements in neuroscience to gain powerful insights into how movement can enhance brain health and combat Alzheimer’s.
Research shows that the brain's waste removal system (the glymphatic system) is most active during sleep and states of deep relaxation. By combining deep relaxation techniques with calibrated spinal movements, we can create a powerful synergy that optimizes these natural processes, enhancing cognitive clarity and overall brain health.
We believe that enhancing CSF circulation through targeted, evidence-based spinal movements could revolutionize brain health, mitigating or reversing neurodegenerative conditions such as Alzheimer’s. Our mission is to develop clinically validated movement protocols and make them accessible to all.
ALZHEIMER'S
The Power of Yoga
At Ciatrix, we’re doing what hasn’t been done before: merging gentle yoga-like movements, mindful breathing, and cutting-edge technology, while rigorously testing it in a clinical trial, to prove, once and for all, that relaxation-based movement therapy truly works.
Our unique approach could give patients and caregivers a new path toward hope and relief. Yoga is a proven method to enhance cognitive clarity, reduce stress, and support brain health, offering significant potential against neurodegenerative diseases. Traditional yoga poses and routines can be challenging for some, including individuals with limited mobility or older adults.
However, yoga’s profound neurological benefits should be accessible to everyone.
By standardizing yoga, testing it in a clinical setting, and making it easier for all to participate, we aim to ensure that people of all ages and abilities can benefit from its ability to support brain health and combat neurodegenerative diseases.
The Fluere™ Device
To test our hypothesis, we have designed and manufactured an innovative device to investigate its potential to promote cerebrospinal fluid flow and, in turn, enhance brain function and overall health.
The Fluere™ device is designed to guide gentle, rhythmic spinal movements. This approach is based on the hypothesis that such movements may create subtle pressure changes, which our clinical trial is investigating for their potential to encourage cerebrospinal fluid (CSF) circulation within the central nervous system.
The REGLYDE clinical trial further aims to explore whether these precise, device-guided motions, by potentially influencing CSF dynamics, could support cognitive function, aspects of neurological health, and overall well-being in individuals with early-stage Alzheimer's disease.
Computer-Guided
Yoga Movement
Gentle Device-Mediated Motions: The Fluere™ device guides the body through safe, subtle movements similar to those found in yoga and qigong.
Mindful Breathing
and Relaxation
Fluere™ uses calming music and guided inhale/exhale cues through headphones with the hopes of promoting deep relaxation, enhancing heart rate variability (HRV), and supporting cognitive and emotional well-being.
Real Time Monitoring and Data Collection
In our clinical trials, we use advanced optical sensors to measure brain fluid flow and assess how movement impacts brain health. Participants also wear activity monitors that track heart rate, HRV, and blood pressure, providing insights into sleep, recovery, and helping us refine and personalize the therapy.
Universal &
Safe Access
Fluere™ is designed for universal access, auto-calibrating each session to the user’s abilities and safely supporting individuals up to 135 kg, including those with some mobility or cognitive challenges.
Diving Deeper: Inside the REGLYDE Clinical Trial
About The Study
This clinical trial investigates the safety, tolerability, and feasibility of the Fluere™ therapy for individuals with early-stage Alzheimer’s disease (AD stages 3 and 4). Over four weeks, participants receive 12 sessions combining movement, rhythmic breathing, and music-guided relaxation.
What We're Studying
The primary goals are to assess how well participants tolerate the therapy and whether a longer regimen is feasible. Secondary goals include monitoring improvements in posture, heart rate variability, sleep quality, cognitive function, and key biomarkers of neurodegeneration.
Study Duration
The treatment period will last for 4 weeks, involving a total of 12 therapy sessions. There is typically a one-week interval between the initial screening visit (T0) and the first therapy session (T1).
ALZHEIMER'S
Why Your Support Matters
Running a transparent and honest clinical trial in today’s climate, which is often riddled with conflicts of interest, requires significant resources.
We need your help to fund:
Multi-Center
Expansion:
To achieve statistical significance and ensure replicability of results, we aim to test Fluere™ at two hospitals in the Czech Republic and one in Slovakia. With additional funding, we plan to expand the study to more centers around the world.
High-Quality Equipment & Participant Care:
Your donations help cover the costs of manufacturing Fluere™ devices, developing monitoring sensors and software, and providing participant compensation and travel reimbursements. This support ensures that everyone can fully commit to the clinical trial.
Research &
Development:
We’ll refine the therapy, establish safety protocols for different fitness levels and disease stages, and continue testing dosage. A rigorous trial with 24 participants and 24 controls will cost $500,000 to $750,000, covering equipment, staff, data analysis, and ethical compliance.
Who are we?
Ciatrix is a team of innovators, scientists, and medical experts united by a mission to revolutionize Alzheimer’s care. By combining cutting-edge neuroscience, innovative technology, and a commitment to improving lives, we’re leading the way in accessible, non-invasive solutions to neurodegenerative diseases.
Zdenko Grajcar
A trailblazer in neurotechnology with 250+ patents, Zdenko blends a passion for innovation with decades of R&D expertise. As Founder and CEO of Ciatrix, he brings a track record of startup success to his mission: creating non-invasive, accessible solutions for millions affected by neurodegenerative diseases.
Founder and CEO
Nash Rittmann, BBA
As Chief Operating Officer, Nash ensures seamless execution of Ciatrix’s initiatives, leveraging his expertise in strategic operations and business development.
Chief Operating Officer
Dr. Katerina Sherdova,PhD
As Head of the Memory Center at ICRC, Dr. Sherdova brings extensive experience in dementia research and preventive care, driving Ciatrix’s innovative therapeutic approaches.
Director of Clinical Research
Dr. Patrik Simko, PhD
A neuroscience advisor and director of clinical research, Dr. Simko specializes in neurodegenerative research and cognitive restoration. With a strong background in data science, neurotech consulting, and clinical research, he brings a holistic approach to advancing brain health.
Clinical Research Consultant
-
What is the Fluere™ device, and how does it work?The Fluere™ device is an innovative medical technology designed to enhance brain health by optimizing the brain’s natural healing mechanisms. It works by improving cerebrospinal fluid (CSF) flow, supporting the glymphatic system, and restoring brain homeostasis. These processes are critical for removing toxins, delivering nutrients, and maintaining cognitive function. Early research suggests that these mechanisms can positively impact memory, cognition, and overall well-being, offering hope for reversing Alzheimer’s and related conditions.
-
Why is this clinical study important?This study is a critical step toward validating the effectiveness of the Fluere™ device in improving cognitive function, memory, and overall brain health. Alzheimer’s disease affects millions worldwide, yet current treatments only manage symptoms without addressing the underlying causes. By scientifically proving the Fluere™ device’s benefits, we aim to provide a groundbreaking, non-invasive option that restores the brain's natural healing abilities.
-
Who will participate in the study, and how will it be conducted?The study will involve individuals diagnosed with Alzheimer’s disease or mild cognitive impairment (MCI), as well as those at risk. Participants will use the Fluere™ device under the supervision of medical professionals, and their cognitive and neurological metrics will be monitored over a specified period. The study will follow rigorous scientific protocols to ensure accuracy, reliability, and ethical standards.
-
How does the Fluere™ device differ from existing Alzheimer’s treatments?Unlike conventional treatments that focus on managing specific symptoms, the Fluere™ device aims to address the root causes of cognitive decline by enhancing the brain’s natural mechanisms for detoxification, nutrient delivery, and homeostasis. It offers a non-invasive, drug-free approach with the potential to reverse or significantly improve symptoms, setting it apart from pharmaceutical options.
-
What kind of results are expected from this study?Based on preliminary research and theoretical models, we expect participants to experience improvements in memory, cognitive function, and overall well-being. Additionally, we anticipate a reduction in disease progression and a better quality of life for both patients and caregivers. The study will help quantify these outcomes and solidify the evidence base for the Fluere™ device.
-
Why are you crowdfunding for this study?All funds raised will go directly toward conducting the clinical study. This includes costs for participant recruitment, compensation, data collection, curation, management (software), analysis, regulatory compliance, clinical research organization (CRO) oversight and device manufacturing and software development/upgrade. Every contribution helps us move closer to proving the efficacy of the Fluere™ device and making it accessible to those who need it most.
-
What are the risks and challenges associated with the study?As with any clinical research, there are challenges, including ensuring participant safety, managing unforeseen variables, and meeting rigorous scientific standards.However, our team of medical and research professionals is committed to minimizing risks through thorough planning, compliance with regulatory guidelines, and ethical oversight.
-
Will contributors to the campaign be able to see the results of the study?Yes, contributors will receive updates on the study's progress and a detailed report of the findings once the study is completed. Transparency is a core value of our mission, and we are committed to sharing how your support has made a tangible impact.
-
Can the Fluere™ device reverse Alzheimer’s disease?While it is too early to make definitive claims, the Fluere™ device is designed to address key mechanisms involved in Alzheimer’s progression. The goal of this study is to determine the device’s effectiveness in slowing, stopping, or reversing the effects of the disease. We remain optimistic based on preliminary data and scientific insights.
-
Is the Fluere™ device available for purchase or use now?Currently, the Fluere™ device is undergoing rigorous clinical testing to validate its safety, feasibility and efficacy. Once the study is successfully completed and regulatory approvals are obtained, we aim to make the device widely available to those who can benefit from it.
-
How can I help beyond contributing to the campaign?You can help by sharing this campaign with your network, spreading awareness about the REGLYDE clinical trial, and engaging with our mission on social media. Every conversation about Alzheimer’s and innovative solutions like Fluere™ helps build momentum for change.
-
What happens if the funding goal is not reached?If we do not reach our full funding goal, we will prioritize essential aspects of the study to ensure we can still gather meaningful data. Your support will have a direct impact on the progress we can achieve, regardless of the final amount raised.
-
How soon can we expect results from the study?The timeline for the study depends on the recruitment and data collection phases, but we aim to complete the study and analyze the results within 12 to 18 months. Regular updates will be provided to all contributors to keep them informed of our progress.